Neurocrine Biosciences
NBIX
#1672
Rank
HK$102.97 B
Marketcap
HK$1,026
Share price
2.17%
Change (1 day)
10.87%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): HK$33.60

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$33.72. In 2024 the company made an earnings per share (EPS) of HK$26.44 an increase over its 2023 EPS that were of HK$19.87.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$33.6027.06%
2024HK$26.4433.07%
2023HK$19.8757.76%
2022HK$12.5969.47%
2021HK$7.43-78.21%
2020HK$34.11990%
2019HK$3.1381.82%
2018HK$1.72-113.5%
2017-HK$12.750.62%
2016-HK$12.6757.28%
2015-HK$8.0625.61%
2014-HK$6.4118.84%
2013-HK$5.40-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$10.64-68.45%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$18.71-44.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$180.08 434.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$0.23-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.88-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$13.38-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$233.90-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$13.82-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK